Lyrica
Product Images NDC 68258-7980

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Lyrica (NDC 68258-7980). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Dispensing Solutions, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Ndc 68258-7980-09 (Ndc 68258 7980 09 Pfizer)

Lyrica 75 mg capsules label from Dispensing Solutions, Inc. The package contains 90 capsules with NDC 68258-7980-09. Each capsule contains 75 mg pregabalin. The label includes dispensing warnings, storage instructions at 77°F, and states prescription only (Rx only). Manufacturer listed is Pfizer Pharmaceuticals LLC, Vega Baja, PR.*

FDA Label Image

Figure (Lyrica 01)

A text panel displaying the formula for calculating creatinine clearance (CLCr), which adjusts for age, weight, and serum creatinine, with a correction factor for female patients. The formula is presented in a mathematical expression format.*

FDA Label Image

Chemical Structure (Lyrica 02)

Chemical structure diagram showing the molecular formula of the active ingredient in the product Lyrica by Dispensing Solutions, Inc. The structure includes an amino group (NH2) and a carboxyl group (CO2H), characteristic of the compound depicted.*

FDA Label Image

Figure 1 (Lyrica 03)

A line graph depicting percent improvement in pain from baseline on the x-axis and percent of patients improved on the y-axis. It compares four groups: Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, Pregabalin 25 mg three times a day, and placebo, showing trends of patient improvement across different dose levels.*

FDA Label Image

Figure 2 (Lyrica 04)

A line chart comparing the percent improvement in pain from baseline on the horizontal axis with the percent of patients improved on the vertical axis. The chart displays two lines, one for Pregabalin 100 mg three times a day and another for Placebo, showing differences in patient improvement rates.*

FDA Label Image

Figure 3 (Lyrica 05)

A line graph showing the percent of patients improved on the vertical axis and percent improvement in pain from baseline on the horizontal axis. The graph compares four curves representing Pregabalin doses of 75 mg, 150 mg, and 300 mg taken twice daily, and a placebo, illustrating the percentage of patients experiencing pain improvement for each treatment.*

FDA Label Image

Figure 4 (Lyrica 06)

A line graph showing the percent of patients improved plotted against percent improvement in pain from baseline. Three lines represent different groups: Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and placebo, allowing comparison of pain improvement outcomes among these groups.*

FDA Label Image

Figure 5 (Lyrica 07)

A line graph showing percent improvement in pain from baseline on the x-axis and percent of patients improved on the y-axis. It compares patients taking Pregabalin 100 mg three times a day, Pregabalin 50 mg three times a day, and a placebo, illustrating differences in pain improvement across these groups over time.*

FDA Label Image

Figure 6 (Lyrica 08)

A bar chart comparing responder rates (%) in two studies (Study E1 and Study E3) across different dosages of a treatment versus placebo. The chart includes bars showing response rates for placebo, 50 mg/day, 300 mg/day, 600 mg/day (Study E1), and 600 mg/day, 900 mg/day (Study E3). Sample sizes (N) are indicated below each bar group.*

FDA Label Image

Figure 7 (Lyrica 09)

Dose-response graph showing the median percentage reduction in seizures from baseline for Lyrica, with data points from four different studies (E1BD, E2TID, E3BD, E3TID). The x-axis represents the dose in mg/day, and the y-axis shows seizure reduction percentage. Significant p-values are indicated, demonstrating statistical differences from placebo at various doses.*

FDA Label Image

Figure 8 (Lyrica 10)

A line graph showing percent of patients improved versus percent improvement in pain from baseline for Lyrica (pregabalin) at different daily doses (300 mg, 450 mg, 600 mg) compared to placebo. The graph illustrates patient improvement trends across varying pain improvement percentages.*

FDA Label Image

Figure 9 (Lyrica 11)

A Kaplan-Meier survival curve comparing the estimated percentage of subjects without LTR (likely an event or condition) over 180 days for Pregabalin versus Placebo. The x-axis represents days from 0 to 180, and the y-axis shows the estimated percentage without LTR from 0% to 100%. The solid line represents Pregabalin and the dashed line represents Placebo, illustrating a higher percentage of subjects without LTR over time with Pregabalin compared to Placebo.*

FDA Label Image

Figure 10 (Lyrica 12)

A line graph showing the percent of subjects improved over a range of percent improvement from baseline to week 12 BOCF, comparing Pregabalin and Placebo. The x-axis represents percent improvement, and the y-axis represents the percent of subjects improved. The graph features two lines: a solid line for Pregabalin and a dashed line for Placebo, with the Pregabalin line consistently higher across the range.*

FDA Label Image

Figure 11 (Lyrica 13)

A Kaplan-Meier style plot comparing the percent of subjects improved over baseline to week 16 between Pregabalin and Placebo. The x-axis represents percent improvement from baseline to week 16 BOCF, ranging from 0 to 100%. The y-axis shows the percent of subjects improved, also from 0 to 100%. Pregabalin is represented by a solid line, and Placebo by a dashed line, with Pregabalin consistently showing higher improvement percentages.*

FDA Label Image

Logo (Lyrica 14)

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.